{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:58:47Z","timestamp":1772524727608,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.eplepsyres.2022.106872","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T07:47:30Z","timestamp":1644047250000},"page":"106872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Changes in the use of antiseizure medications in children and adolescents in Norway, 2009\u20132018"],"prefix":"10.1016","volume":"181","author":[{"given":"Katrine","family":"Heger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Skipsfjord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yury","family":"Kiselev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margrete Larsen","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari M.","family":"Aaberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilie","family":"Johannessen Landmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0921","article-title":"Comorbidity and childhood epilepsy: a nationwide registry study","volume":"138","author":"Aaberg","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.106872_bib2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3908","article-title":"Incidence and prevalence of childhood epilepsy: a nationwide cohort study","volume":"139","author":"Aaberg","year":"2017","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.106872_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders - a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2022.106872_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2017.11.001","article-title":"Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: a pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015","volume":"139","author":"Baftiu","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.106872_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eplepsyres.2016.04.003","article-title":"Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study","volume":"123","author":"Brodie","year":"2016","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic drug monitoring of clobazam and its metabolite - impact of age and comedication on pharmacokinetic variability","volume":"38","author":"Burns","year":"2016","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.eplepsyres.2022.106872_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fpsyt.2018.00270","article-title":"Anticonvulsants for psychiatric disorders in children and adolescents: a systematic review of their efficacy","volume":"9","author":"Davico","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106872_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007711","article-title":"Safety of lamotrigine in paediatrics: a systematic review","volume":"5","author":"Egunsola","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.eplepsyres.2022.106872_bib9","unstructured":"European Medicines Agency, 2021. Vimpat Assessment History. \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vimpat#assessment-history-section\u3009. (Accessed 26 August 2021)."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.106872_bib10","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD) \u2013 new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"Furu","year":"2008","journal-title":"Nor. Epidemiol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.106872_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/cns.12399","article-title":"Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy","volume":"21","author":"Gauthier","year":"2015","journal-title":"CNS Neurosci. Ther."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/epi4.12413","article-title":"A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway","volume":"5","author":"Heger","year":"2020","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2022.106872_bib14","unstructured":"Hirsch, E., French, J., Scheffer, I., Zuberi, S., Trinka, E., Specchio, N., et al., 2021. Draft: Definition of the Idiopathic Generalized Epilepsy Syndromes: Position Paper by the ILAE Task Force on Nosology and Definitions. \u3008https:\/\/www.ilae.org\/files\/dmfile\/IGEFINALApril2.pdf\u3009. (Accessed 30 September 2021)."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.106872_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.07.005","article-title":"Antiepileptic drugs in epilepsy and other disorders\u2014a population-based study of prescriptions","volume":"87","author":"Johannessen Landmark","year":"2009","journal-title":"Epilepsy Res"},{"issue":"1\u20132","key":"10.1016\/j.eplepsyres.2022.106872_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Johannessen Landmark","year":"2011","journal-title":"Epilepsy Res."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106872_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Johannessen Landmark","year":"2016","journal-title":"Epileptic Disord."},{"issue":"Pt A","key":"10.1016\/j.eplepsyres.2022.106872_bib18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yebeh.2019.05.021","article-title":"Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"98","author":"Johannessen Landmark","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.106872_bib19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bcpt.12981","article-title":"Utilization of antiepileptic medicines in Swedish children and adolescents with different diagnoses","volume":"123","author":"Karlsson Lind","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2022.106872_bib20","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00228-010-0861-y","article-title":"Psychiatric comorbidity in patients with epilepsy: A population-based study","volume":"66","author":"Karouni","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.106872_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-017-0776-4","article-title":"Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials","volume":"18","author":"Le","year":"2017","journal-title":"J. Headache Pain."},{"issue":"9566","key":"10.1016\/j.eplepsyres.2022.106872_bib22","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2022.106872_bib23","unstructured":"National Institute for Health and Care Excellence, 2012. Clinical Guideline: 1.9 Pharmacological Treatment. \u3008https:\/\/www.nice.org.uk\/guidance\/cg137\/chapter\/1-Guidance#pharmacological-treatment\u3009. (Updated 12 May 2021); (Accessed 26 September 2021)."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.yebeh.2012.09.018","article-title":"Antiepileptic drug effects on mood and behavior: molecular targets","volume":"26","author":"Perucca","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1592\/phco.31.3.298","article-title":"Vigabatrin for infantile spasms","volume":"31","author":"Pesaturo","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eplepsyres.2022.106872_bib26","unstructured":"Specchio, N., Wirrell, E.C., Scheffer, I.E., Nabbout, R., Riney, K., Samia, P., et al., 2021. Draft: ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions. \u3008https:\/\/www.ilae.org\/files\/dmfile\/CHILDApril6withfigs.pdf\u3009. (Accessed 30 September 2021)."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.106872_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108970","article-title":"Valproic acid and fatalities in children: a review of individual case safety reports in VigiBase","volume":"9","author":"Star","year":"2014","journal-title":"PLoS One"},{"key":"#cr-split#-10.1016\/j.eplepsyres.2022.106872_bib28.1","unstructured":"Statistics Norway, 2021. Statbank. Table 07459: Population, by Sex and One-year Age Groups"},{"key":"#cr-split#-10.1016\/j.eplepsyres.2022.106872_bib28.2","unstructured":"(M) 1986-2021. \u3008https:\/\/www.ssb.no\/en\/statbank\/table\/07459\/\u3009. (Accessed 20 August 2021)."},{"issue":"18","key":"10.1016\/j.eplepsyres.2022.106872_bib29","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.4045\/tidsskr.15.0454","article-title":"Prevalence and incidence of epilepsy in the Nordic countries","volume":"135","author":"Syvertsen","year":"2015","journal-title":"Tidsskr. Nor. Laegeforen"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.106872_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.106872_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106872_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","article-title":"Pharmacotherapy for Dravet Syndrome","volume":"18","author":"Wallace","year":"2016","journal-title":"Paediatr. Drugs"},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.106872_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","article-title":"Levetiracetam monotherapy in children with epilepsy: A systematic review","volume":"29","author":"Weijenberg","year":"2015","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.106872_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/pds.3457","article-title":"The Nordic prescription databases as a resource for pharmacoepidemiological research - a literature review","volume":"22","author":"Wettermark","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2022.106872_bib35","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, 2018. DDD. Definition and General Considerations. \u3008https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/\u3009. (Updated 7 Febuary 2018); (Accessed 27 July 2021)."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:17:53Z","timestamp":1741918673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"alternative-id":["S0920121122000237"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106872","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in the use of antiseizure medications in children and adolescents in Norway, 2009\u20132018","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106872"}}